Related Experiment Videos
Effect of BN 52021, a platelet activating factor antagonist, on experimental murine contact dermatitis
1Department of Dermatology, University of Münster, F.R.G.
Abstract:
A specific platelet activating factor (PAF) receptor antagonist, BN 52021, was tested for its efficacy in modulating DNFB-induced allergic and croton oil-induced irritant contact dermatitis in mouse ears. Oral treatment of the animals in the elicitation phase of the dermatitis caused a significant suppression of DNFB-induced ear swelling. The compound was less active in croton oil-induced irritant dermatitis and ineffective when given during the sensitization phase of allergic dermatitis. The results provide indirect evidence for the involvement of PAF in the effector phase of murine contact dermatitis of the allergic type and also the irritant type to a lesser extent.
Insights
Platelet activating factor (PAF) receptor antagonist BN 52021 significantly suppressed allergic contact dermatitis in mice. It showed less efficacy in irritant dermatitis and was ineffective during sensitization.
Area of Science:
- Immunology
- Dermatology
- Pharmacology
Background:
- Contact dermatitis involves allergic and irritant types.
- Platelet-activating factor (PAF) is implicated in inflammatory responses.
Purpose of the Study:
- To investigate the efficacy of PAF receptor antagonist BN 52021 in mouse models of allergic and irritant contact dermatitis.
Main Methods:
- Mice were sensitized and challenged with 2,4-dinitrofluorobenzene (DNFB) for allergic dermatitis.
- Irritant contact dermatitis was induced using croton oil.
- BN 52021 was administered orally during the elicitation or sensitization phase.
Main Results:
- Oral BN 52021 significantly suppressed DNFB-induced ear swelling during the elicitation phase.
- BN 52021 demonstrated reduced activity in croton oil-induced dermatitis.
- The compound was ineffective when administered during the sensitization phase of allergic dermatitis.
Conclusions:
- PAF plays a role in the effector phase of allergic contact dermatitis.
- PAF is involved to a lesser extent in irritant contact dermatitis.
- BN 52021's efficacy suggests PAF receptor antagonism as a potential therapeutic strategy.